

15

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number  
WO 01/54746 A2

- (51) International Patent Classification<sup>7</sup>: A61L 27/00
- (21) International Application Number: PCT/US01/03219
- (22) International Filing Date: 31 January 2001 (31.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/179,238 31 January 2000 (31.01.2000) US
- (71) Applicant (for all designated States except US): ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. [US/US]; Suite 100, 1100 Waterway Boulevard, Indianapolis, IN 46202-2156 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ROEDER, Ryan, K. [US/US]; 7149 Eagle Cove N. Drive, Indianapolis, IN 46254 (US). TURNER, Charles, H. [US/US]; 2830 Granada CW, Indianapolis, IN 46222 (US).
- (54) Title: COMPOSITE BIOMATERIAL INCLUDING ANISOMETRIC CALCIUM PHOSPHATE REINFORCEMENT PARTICLES AND RELATED METHODS
- (74) Agents: HASAN, Salim, A. et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/54746 A2



surface-active agent  
(Claims 24, 62)  
+  
nanosized  
peptide  
poly  
p12 needle-like  
anisometric particles  
of calcium  
phosphate  
hydroxyapatite  
re U.S. 5227147

(57) Abstract: Composite biomaterials (e.g., for use as orthopedic implants), as well as methods of preparing composite biomaterials, are disclosed. The composite biomaterial includes a matrix (e.g., a continuous phase) comprising a thermoplastic, a calcium phosphate composition that is curable *in vivo*, or combinations thereof. The composite biomaterial also includes an isometric calcium phosphate reinforcement particles which are dispersed within the matrix.

**COMPOSITE BIOMATERIAL INCLUDING ANISOMETRIC  
CALCIUM PHOSPHATE REINFORCEMENT PARTICLES AND  
RELATED METHODS**

5

**CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application claims the benefit of U.S. application 60/179,238, filed on January 31, 2000, which is hereby incorporated in its entirety by reference.

10

**TECHNICAL FIELD OF THE INVENTION**

This invention pertains generally to biomaterials. More particularly, the present invention relates to a composite biomaterial that can be used, for example, as an orthopedic implant.

15

**BACKGROUND OF THE INVENTION**

Orthopedic implants are used commonly as structural reinforcements in the human body. By way of example, orthopedic implants are used to strengthen failed bone (e.g., broken or deteriorating bone), to stiffen compromised vertebrae, or to eliminate painful arthritic or damaged joints. Most orthopedic implants presently in use involve the extensive use of permanent metal hardware, such as, for example, bone plates and screws and spine cages.

20

Despite the enhanced mechanical strength and stiffness associated with them, such traditional metallic orthopedic implants require invasive surgical techniques which impose a large degree of surgical trauma, suffering, and rehabilitation time on patients. As an example, the treatment of hip fractures often requires an incision that is twelve inches or longer. Furthermore, when a stiff metal plate or implant is attached to bone, it tends to "shield" the bone tissue from mechanical stresses, and, under these conditions, native bone undesirably tends to resorb away.

25

30

Nevertheless, finding suitable alternative biomaterials has proven to be difficult. Particularly, existing non-metal biomaterials have not been satisfactory,

for example, because they are inadequate with respect to mechanical properties (e.g., strength). For example, dense ceramics would have similar problems because they are stiff, and, thus, are stress shielding, and they have the additional drawback of being brittle such that they have a lower fracture toughness. In addition, non-metal biomaterials, such as, for example, existing polymeric and porous ceramic biomaterials are significantly inferior to natural cortical bone in terms of mechanical properties, such as, for example, elastic modulus, tensile strength, and compressive strength.

By way of example, one alternative approach to the use of metals in the field of orthopedics involves minimally invasive orthopedic implant surgical techniques in which injectable bone glue and filler materials are used (e.g., to repair a bone fracture) instead of metal plates and screws and the like. As an example, the "skeletal replacement system" (SRS) offered by Norian Corporation (Cupertino CA) involves an injectable cementitious material that cures after injection in the body (i.e., *in vivo*). However, the SRS material has proven to be unsatisfactory for many load bearing applications because of its inferior tensile properties and low fracture toughness.

In addition, noteworthy among polymeric materials is the polymethyl methacrylate (PMMA) cement. The PMMA cement also suffers from insufficient mechanical properties, which, while generally better than SRS, are still inferior to those of natural cortical bone. In addition, another shortcoming associated with PMMA cement is that a large amount of heat is generated undesirably during the exothermic curing process. The heat generated during the exothermic curing reaction limits the volume of a bone defect that can be filled inasmuch as a large volume of bone cement will generate sufficient heat to kill adjacent tissues. Furthermore, PMMA cement also has a tendency to leach out MMA monomer that can have toxic effects on nearby tissues.

Accordingly, it will be appreciated from the foregoing that there exists a need in the art for a biomaterial (e.g., for orthopedic implants) with desirable biomechanical properties, as well as methods of preparing such biomaterials. It is an object of the present invention to provide such a biomaterial and related

methods. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

5

### BRIEF SUMMARY OF THE INVENTION

The present invention provides a composite biomaterial as well as methods of preparing composite biomaterials. The composite biomaterial includes anisometric calcium phosphate reinforcement particles that are dispersed within a matrix. The matrix comprises a thermoplastic polymer, a calcium-phosphate  
10 composition that is curable *in vivo* (e.g., in a mammal), or any combination thereof.

In another aspect of the present invention, provided is a method of preparing a composite biomaterial comprising (a) a matrix including a calcium phosphate composition that is curable *in vivo* and (b) anisometric calcium  
15 phosphate reinforcement particles arranged within the matrix. The method comprises providing the anisometric calcium phosphate reinforcement particles. The method also includes preparing the calcium phosphate composition from at least one calcium-containing compound and at least one phosphate-containing compound. At least one of the calcium-containing compound and phosphate-  
20 containing compound is derived by a hydrothermal reaction. In addition, the method comprises combining the anisometric calcium phosphate reinforcement particles with the calcium phosphate composition or, alternatively, with at least one of the calcium-containing compound or phosphate-containing compound prior to formation of the calcium phosphate composition.

25 In addition, in another aspect, the present invention provides a method of preparing a composite biomaterial comprising (a) a matrix including a thermoplastic polymer and (b) anisometric calcium phosphate reinforcement particles arranged within the matrix. The method comprises providing the anisometric calcium phosphate reinforcement particles and providing the polymer.  
30 The method also includes co-processing the polymer and the calcium phosphate reinforcement particles to obtain a substantially uniform mixture thereof. In

addition, the method comprises deforming and/or densifying the mixture to form the composite biomaterial.

The invention may best be understood with reference to the accompanying drawings and the following detailed description of the preferred embodiments.

5

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of a whisker-shaped anisometric reinforcement particle, in accordance with the present invention.

FIG. 2 is a schematic representation of a platelet-shaped anisometric reinforcement particle, in accordance with the present invention.

FIG. 3 is a schematic representation of a cross-section of a composite biomaterial, illustrating anisometric reinforcement particles dispersed in a matrix in an aligned manner, in accordance with a preferred embodiment of the present invention.

FIG. 4A illustrates a scanning electron microscopy (SEM) micrograph of conventional calcium hydroxyapatite (HA) powder.

FIG. 4B illustrates an SEM micrograph of HA whiskers.

FIG. 4C illustrates an optical micrograph of high density polyethylene (HDPE) powder.

FIG. 5A illustrates x-ray diffraction patterns (XRD) of HA crystals in a human cortical bone (femoral midshaft) specimen.

FIG. 5B illustrates XRD patterns for HA crystals in an exemplary synthetic HDPE-HA composite that includes 30% by volume HA.

FIG. 6A illustrates Harris texture index measurements of HA crystals in a human cortical bone (femoral midshaft) specimen.

FIG. 6B illustrates Harris texture index measurements of HA crystals in an exemplary synthetic HDPE-HA composite that includes 30% by volume HA.

### DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated, at least in part, on providing composite biomaterials that are biocompatible and have desirable biomechanical properties

(e.g., resembling those of natural bone). The biomaterials include a matrix (e.g., continuous phase or continuum) of, for example, a thermoplastic polymer, a calcium phosphate composition, or suitable combinations thereof. Significantly, the composite biomaterials of the present invention also include calcium phosphate reinforcement particles, which are dispersed within the matrix, in order to provide mechanical reinforcement. In accordance with the present invention, the calcium phosphate reinforcement particles are either single crystals or dense polycrystals and are anisometric (as opposed to equiaxed) in nature such that the reinforcement particles exhibit different properties in different orientations or crystallographic directions. As a result of the anisometric nature of the reinforcement particles, especially if aligned (as discussed herein below), the inventive composite biomaterials possess enhanced biomechanical properties. The composite biomaterials of the present invention have significant utility, for example, in mammalian orthopedic implants (e.g., as a prosthesis for replacement of bone).

The matrix can be bioresorbable (i.e., a material capable of being resorbed by a patient, e.g., a mammal, under normal physiological conditions) or non-bioresorbable, as desired. In this respect, in some applications, it is desirable that the biomaterial be bioresorbable by the patient, such as, for example, in younger patients where bone regeneration occurs readily. Desirably, in some embodiments, bioresorbable materials are selected so as to be tailored to the particular patient's own bone regeneration process such that the bioresorbable material would be replaced gradually over time by the patient's own natural (regenerated) tissue.

In other applications, non-bioresorbability is desirable, e.g., in older patients where bone regeneration is retarded, so that the biomaterial remains inert and demonstrates little degradation in biomechanical properties. However, the decision of whether to use a bioresorbable or non-bioresorbable biomaterial depends on many factors including the patient's health profile, the degree of injury, and the procedure preferred by the surgeon.

The biomaterial can be percutaneously injected, surgically injected, or surgically implanted, depending upon the material or materials selected for the matrix. By way of example, in embodiments where a major portion of the matrix is a calcium phosphate composition or a thermoplastic polymer composition that exhibits flowability initially but is capable of curing (setting up) *in vivo* in a mammalian host after some period of time, percutaneous or surgical injection (e.g., via a needle, catheter, glue gun or the like) can be utilized to deliver the inventive biomaterial while in the flowable state to the desired *in vivo* location. In other embodiments, the initially flowable composition can be cured and formed into a desired shape *ex vivo* and surgically implanted. In still other embodiments, for example, where a major portion of the matrix includes a calcium phosphate composition or a thermoplastic polymer composition where *in vivo* delivery by injection and/or curing is not possible or sufficiently limited, the biomaterial can be appropriately shaped by the surgeon and surgically implanted.

Any suitable calcium phosphate composition (e.g., cement) or thermoplastic material, as well as suitable combinations thereof, can be included in the matrix. By way of example, and not limitation, examples of suitable calcium phosphate compounds for inclusion (alone or in combination) in the calcium phosphate composition are listed in Table I. In addition, one or more dopants (e.g., sodium, potassium, magnesium, carbonate, fluoride, chloride, and the like) optionally can be included in the calcium phosphate composition. If included, the dopants preferably are included in an amount of less than about 10% by weight of the calcium phosphate composition.

Table I: Exemplary Calcium Phosphate Compounds

Abbrev	Chemical Formula	Chemical Name	Mineral Name
ACP	$\text{Ca}_x(\text{PO}_4)_y$	Amorphous calcium phosphate	
BCP	$(\text{Ca}_{10}(\text{PO}_4)_6\text{OH})_x + (\text{Ca}_3(\text{PO}_4)_6)_{1-x}$	biphasic calcium phosphate	
CP		calcium phosphate	
DCP	$\text{CaHPO}_4$	dicalcium phosphate	Monetite
DCPD	$\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$	dicalcium phosphate dihydrate	Brushite
HA or OHAp	$\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$	calcium hydroxyapatite	Apatite or hydroxyapatite
$\text{CO}_3\text{Ap}$	$\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ with $\text{CO}_3$ 's substituting $\text{PO}_4$ 's and/or $\text{OH}$ 's	carbonated calcium hydroxyapatite	Carbonate apatite
MCP	$\text{Ca}(\text{H}_2\text{PO}_4)_2$	monocalcium phosphate	
MCPM	$\text{Ca}(\text{H}_2\text{PO}_4)_2 \cdot \text{H}_2\text{O}$	monocalcium phosphate monohydrate	
OCP	$\text{Ca}_8\text{H}_2(\text{PO}_4)_6 \cdot 5\text{H}_2\text{O}$	octacalcium phosphate	
TCP	$\text{Ca}_3(\text{PO}_4)_2$	tricalcium phosphate	
$\alpha$ -TCP	$\alpha\text{-Ca}_3(\text{PO}_4)_2$	alpha-tricalcium phosphate	
$\beta$ -TCP	$\beta\text{-Ca}_3(\text{PO}_4)_2$	beta-tricalcium phosphate	
TTCP	$\text{Ca}_4(\text{PO}_4)_2\text{O}$	Tetra-calcium phosphate	Hilgenstockite

As will be appreciated by one skilled in the art, the bioresorbability of these calcium phosphate compounds varies according to crystal chemistry.

- 5 Referring now to thermoplastic polymers, examples of bioresorbable thermoplastics include, but are not limited to, poly(DL-lactide) (DLPLA), poly(L-lactide) (LPLA), poly(glycolide) (PGA), poly( $\epsilon$ -caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate) (PHV), poly(orthoesters), poly(carboxylates),
- 10 poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides),



poly(iminocarbonates), poly(phosphazenes), and the like, as well as copolymers or blends thereof, and combinations thereof.

Examples of non-bioresorbable thermoplastics include, but are not limited to, polyethylenes, such as high density polyethylene (HDPE), ultra high molecular weight polyethylene (UHMWPE), and low density polyethylene (LDPE), as well as polybutylene, polystyrene, polyurethane, polypropylene, polyacrylates, polymethacrylates, such as polymethylmethacrylate (PMMA), and polymerized monomers such as tri(ethylene glycol) dimethacrylate (TEG-DMA), bisphenol A hydroxypropyl methacrylate (bis-GMA), and other monomers listed herein below, and the like, as well as copolymers or blends thereof and combinations thereof.

In some embodiments, the matrix can include a combination of calcium phosphate compounds, a combination of thermoplastics, or a combination of one or more calcium phosphate compounds and one or more thermoplastics. Strictly by way of example, in some embodiments, the matrix can include a combination of at least one non-bioresorbable material (e.g., thermoplastic or calcium phosphate) and at least one bioresorbable material. For example, the matrix can include at least one calcium phosphate compound as well as particulate or dissolved (e.g., in water or other suitable biocompatible medium) thermoplastic.

Desirably, in some embodiments in which the matrix includes a combination of a non-bioresorbable material and a bioresorbable material, the matrix can be arranged so that the concentration of the bioresorbable component is higher at or near the matrix surface. In this respect, the bioresorbable component can be graded from the matrix surface to the inner core of the matrix.

With respect to the reinforcement particles, the particular calcium phosphate utilized for the reinforcement particles can be selected, for example, from the list in Table I, as well as combinations thereof. Dopants or other additives can be included within the reinforcement particles, if desired. In accordance with the present invention, the calcium phosphate reinforcement particles are in the form of single crystals or dense polycrystals, and are anisometric in nature. For example, the calcium phosphate reinforcement particles can be in the shape of whiskers 12, as shown in FIG. 1, or in the shape of

platelets 14, as shown in FIG. 2. In particular, the reinforcement particles are characterized as having a c-axis 16, which is the longest orthogonal axis, and an a-axis 18, which is the shortest orthogonal axis, as shown in FIGS. 1 and 2. Pursuant to the present invention, inasmuch as the reinforcement particles are anisometric (and not equiaxed), the respective lengths along the c-axis and the a-axis are different. In this respect, the reinforcement particles of the present invention are characterized as having a mean aspect ratio (length along c-axis/length along a-axis) of greater than 1 and less than 100. Preferably, the mean aspect ratio of the reinforcement particles is from about 5 to about 50, more preferably, from about 7.5 to about 35, and still more preferably, from about 10 to about 20.

The reinforcement particles can be of any suitable size. For example, in some embodiments, the reinforcement particles have mean dimensions of from about 1 micrometer to about 500 micrometers along the c-axis and from about 0.02 micrometers to about 20 micrometers along the a-axis. Other exemplary mean dimensions include a length of from about 5 micrometers to about 50 micrometers along the c-axis and a length of from about 0.1 micrometer to about 10 micrometers along the a-axis. Additional exemplary mean dimensions include a length of from about 10 micrometers to about 40 micrometers along the c-axis and a length of from about 0.2 micrometers to about 8 micrometers along the a-axis.

In addition, some smaller, (e.g., nano-sized) calcium phosphate reinforcement particles can be included as well. For example, the nano-sized (e.g., mean dimensions of from about 1 nanometers to about 500 nanometers) can be in the form of bioresorbable particles, in which case the smaller size would be advantageous because resorption would occur more readily. Desirably, if present, the nano-sized reinforcement particles are concentrated more heavily at or near the matrix surface. In particular, if present, the nano-sized calcium phosphate reinforcement particles preferably are graded from the matrix surface to the inner core of the matrix.

The reinforcement particles can be included in any suitable amount in the inventive composite biomaterial. For example, the reinforcement particles can be

provided in an amount of from about 1% by volume of the composite biomaterial to about 60% by volume of the composite biomaterial, more preferably, from about 30% by volume of the composite to about 60% by volume of the composite, still more preferably, from about 40% by volume of the composite to about 60% by volume of the composite.

Notably, the calcium phosphate reinforcement particles provide mechanical reinforcement (e.g., strength and/or fracture toughness), for example, because of their anisometric morphology and because of their nature as single-crystals or dense polycrystals which have greater inherent mechanical properties as compared to the matrix. With respect to morphology, because the reinforcement particles geometrically are anisometric, the particles effectively reinforce the biomaterial. Particularly, the anisometric reinforcement particles 10 can be provided so that they are dispersed in the matrix 20, preferably so that there is overlap between particles, as seen in FIG. 3, so that reinforcement is enhanced. For purposes of clarity, the term "dispersed" does not preclude some contact between particles.

The reinforcement particles can be randomly oriented (i.e., unaligned) in some embodiments. However, as seen in FIG. 3, the reinforcement particles 10 preferably are predominately aligned within the matrix 20. Crystallographic or morphological alignment (e.g., a preferred orientation) of the reinforcement particles within the matrix 20 results in anisotropy for the overall composite 22. By way of contrast, if the reinforcement particles are randomly oriented (i.e., no preferred orientation) within the matrix, the overall composite possesses isotropic properties. Composites exhibiting anisotropic properties, that is, having different properties in different directions of the composite, possess enhanced mechanical properties in one or two directions of the composite over composites exhibiting isotropic properties, that is, having equal properties in all directions, all else being equal. In many cases (for example, the long shaft of the femur), the unique mechanical properties possessed by native human bone are due to anisotropy.

As used herein, the term "aligned" reinforcements will be understood by those of ordinary skill in the art as a preferred crystallographic or morphological orientation. The preferred orientation or texture of a material is most accurately

measured quantitatively by way of an orientation distribution function (ODF). An ODF can be measured using x-ray diffraction pole figure analysis and/or stereological analysis, as described by Sandlin *et al.*, "Texture Measurement on Materials Containing Platelets Using Stereology," *J. Am. Ceram. Soc.*, 77 [8] 2127-2131 (1994). In these quantitative techniques, a random ODF is assigned a value of 1, such that values greater than 1 indicate a preferred (aligned) orientation in multiples of a random distribution (MRD). In accordance with preferred embodiments of the invention, the reinforcement particles are aligned in the matrix such that they have an ODF pursuant to this quantitative technique of greater than 1 MRD, more preferably, an ODF of at least about 2 MRD, even more preferably an ODF of at least about 3 MRD, still more preferably, an ODF of at least about 4 MRD, even more preferably an ODF of at least about 5 MRD, e.g., an ODF of from about 5-20 MRD, which approximately corresponds to that of the human femur. In some embodiments, it is desirable to have an even higher ODF, for example, an ODF of at least about 20, to achieve mechanical anisotropy in the synthetic composite biomaterial that matches the host's bone material

As will be appreciated by those of ordinary skill in the art, semi-quantitative techniques of identifying the preferred (aligned) orientation or texture of a material are described by Harris (see, e.g., "Quantitative Measurement of Preferred Orientation in Rolled Uranium Bars," *Phil. Mag.* 43 [336] 113-123 (1952); and Peterson *et al.*, "X-Ray Texture Analysis of Oriented PZT Thin Films," *Mat. Res. Soc. Symp. Proc.*, 433, 297-302 (1996)) and Lotgering (see, e.g., "Topotactical Reactions with Ferrimagnetic Oxides Having Hexagonal Crystal Structures - I," *J. Inorg. Nucl. Chem.*, 9, 113-123 (1959)). It will be appreciated that under the Harris technique, a random orientation also is assigned a value of 1, while in the Lotgering technique, the random orientation is assigned a value of zero. Thus, a preferred, or aligned, orientation would have a value greater than 1 or zero, respectively, under these semi-quantitative techniques.

In addition to their morphology, the inherent strength of the reinforcement particles, which is greater than that of the matrix, enhances the mechanical strength of the composite. In this respect, whereas the matrix can include a porous

material of polycrystals (e.g., cement), the reinforcement particles are not porous and are unitary crystals. The porosity of the matrix is biologically advantageous but undesirable with respect to mechanical strength. Accordingly, the reinforcement particles enhance the mechanical strength of the composite biomaterial of the present invention.

The inventive composite biomaterial optionally can include additives, if desired. By way of example, the biomaterial can include one or more surface-active agents in order to enhance interfacial bonding between the reinforcement particles and the matrix. As other examples, the inventive biomaterial can include one or more growth factors, including, but not limited to, those in the TGF-beta super family (e.g., TGF-betas, bone morphogenic proteins, such as, for example, BMP-2, BMP-7 or the like, etc.), fibroblast growth factors, epidermal growth factors, vascular endothelial growth factors, insulin-like growth factors, or interleukins, to enhance osteoinductivity and/or bone regeneration. Furthermore, the inventive biomaterial can include one or more transcription factors or matrix metalloproteinases to improve bone regeneration, or speed resorption and replacement of the biomaterial. In addition, the biomaterial can be coated with one or more peptides or proteins that enhance attachment of bone cells (e.g., osteopontin, integrins, matrix receptors, RGD, or the like).

The anisometric calcium phosphate particles can be prepared in any suitable manner. Suitable techniques are described, for example, in U.S. Patent No. 5,227,147; Fujishiro et al., "Preparation of Needle-like Hydroxyapatite by Homogeneous Precipitation under Hydrothermal Conditions," *J. Chem. Technol. Biotechnol.*, 57, 349-353 (1993); Yoshimura et al. "Hydrothermal Synthesis of Biocompatible Whiskers," *J. Mater. Sci.*, 29, 3399-3402 (1994); Suchanek et al., "Biocompatible Whiskers with Controlled Morphology and Stoichiometry," *J. Mater. Res.*, 10 [3] 521-529 (1995); Kandori et al., "Texture and Formation Mechanism of Fibrous Calcium Hydroxyapatite Particles Prepared by Decomposition of Calcium-EDTA Chelates," *J. Am. Ceram. Soc.*, 80 [5] 1157-1164 (1997); Nakahira et al., "Novel Synthesis Method of Hydroxyapatite Whiskers by Hydrolysis of  $\alpha$ -Tricalcium Phosphate in Mixtures of Water and

Organic Solvent," *J. Am. Ceram. Soc.*, 82 [8] 2029-2032 (1999); and Katsuki et al., "Microwave- Versus Conventional-Hydrothermal Synthesis of Hydroxyapatite Crystals from Gypsum," *J. Am. Ceram. Soc.*, 82 [8] 2257-2259 (1999).

In some embodiments, the reinforcement particles can be produced by way of a hydrothermal reaction, e.g., at low temperatures (such as, for example, from about 37 °C to about 200 °C) from chemical solutions containing chemical reactant precursors, pH modifying precursors, and/or chelating acids. In particular, the reactant precursors can be in the form of a calcium-containing compound and a phosphate-containing compound, both of which are selected such that they exhibit greater solubility in water than the solubility in water of the calcium-containing reinforcement particles desired to be produced (e.g., via precipitation or ion exchange in solution). Examples of such calcium-containing compounds include, but are not limited to, the compounds listed in Table I, as well as calcium hydroxide, calcium nitrate, calcium chloride, calcium carbonate, calcium lactate, calcium acetate, calcium citrate, calcium sulfate, calcium fluoride, calcium oxalate, and the like, as well as combinations thereof. Examples of phosphate-containing compounds include, but are not limited to, the compounds listed in Table I, as well as phosphoric acid, fluorophosphoric acid, sodium orthophosphate, potassium orthophosphate, ammonium orthophosphate, and the like, as well as combinations thereof. It will be appreciated that pH modifying precursors can include any suitable acid or base. Chelating acids can include, for example, formic acid, acetic acid, lactic acid, valeric acid, ethylenediaminetetracetic acid (EDTA), glycolic acid, oxalic acid, citric acid, and the like, as well as combinations thereof.

Producing the reinforcement particles hydrothermally is desirable because the size and morphology of the resulting reinforcement particles can be controlled readily, for example, by adjusting the reactant concentrations solution pH, type of chelating acid, reaction heating rate, mixing reaction temperature, and length of reaction. Reaction temperatures, for example, greater than 100 °C, are especially conducive to whisker formation. It is to be noted, however, that reactions at

temperatures greater than 100 °C require a pressure vessel that is suitably lined (e.g., with TEFLON®) to contain the pressurized aqueous solution.

Turning now to the preparation of the composite biomaterials, a matrix including at least one calcium phosphate composition (that is curable *in vivo*) can be prepared from one or more calcium-containing and one or more phosphate-containing reactant compounds. Notably, at least one of the calcium-containing or phosphate-containing reactant compounds is derived by a hydrothermal reaction. In some embodiments, both the calcium-containing and phosphate-containing reactant compounds are derived hydrothermally.

Particularly, by utilizing a hydrothermal reaction to derive at least one of the calcium-containing and phosphate-containing reactant compounds, the resultant reactant compounds can be produced so as to have a very fine size and controlled purity. Preferably, at least one of the calcium-containing and phosphate-containing reactant compounds is characterized by particles having a mean diameter of less than about 1 micrometer, more preferably, a mean diameter of from about 1 nanometer to about 500 nanometers, even more preferably, from about 1 nanometer to about 100 nanometers. By starting with a smaller grain size for one or both of the calcium-containing and phosphate containing reactant compounds, the resulting calcium phosphate matrix composition also would be in the form of smaller particles (e.g., polycrystals). The smaller size of the particles of the calcium phosphate matrix composition results in a matrix of enhanced mechanical strength.

The calcium-containing and phosphate-containing reactant compounds can be selected, for example, from the respective lists of calcium-containing and phosphate-containing chemical precursors discussed herein above with respect to the reinforcement particles. To produce the calcium phosphate matrix composition, the calcium-containing and phosphate-containing reactant compounds can be mixed, for example, while dry (e.g., in powder form). In some embodiments, the powders can be mixed with phosphoric acid crystals and ground with mortar and pestle. In addition, as an example, a sodium phosphate solution can be added to form a flowable paste, which is injectable into a patient and which

is capable of curing *in vivo* in a mammalian host after injection at the desired locus (e.g., bone, such as the femur or vertebrae). In this respect, the paste desirably is formed, for example, in the operating room, shortly before delivery (e.g., by injection) into the patient where it can then harden *in vivo*. In other embodiments, the compounds can be prepared in two separate flowable pastes which can be stored separately, and later mixed together and injected at the desired locus where it can harden *in vivo*.

The calcium phosphate reinforcement particles can be added prior to formation of the calcium phosphate composition (e.g., added to one or both of the calcium-containing compound(s) and phosphate-containing compound(s)) and/or after the calcium phosphate composition is formed.

With respect to the preparation of a composite biomaterial comprising a matrix that includes at least one thermoplastic polymer, a substantially uniform mixture of polymer and calcium phosphate reinforcement particles is formed via co-processing. By way of example, in some embodiments, a preform is made from polymer provided in the form of particles. The polymer particles can be produced in any suitable manner. For example, the polymer can be dissolved in any suitable solvent in which the polymer can be dissolved (e.g., water, xylene, chloroform, toluene, methylene chloride, tetrahydrofuran, ethyl acetate, hexafluoroisopropanol, acetone, alcohols, and the like). In such embodiments, the polymer particles can be formed by precipitation or gelation from the solution, for example, under rapid mixing. The solvent is then removed, e.g., by vacuum oven drying, distillation and collection, freeze drying, and the like. Additionally, the polymer particles and/or gel may be suspended in a suitable medium (e.g., water, alcohols, and the like) and homogenized by high shear mixing to provide a uniform distribution of particles or repeatedly washed to remove residual traces of the solvent. The polymer particles and the calcium phosphate reinforcement particles each are suspended in a suitable medium for dispersing the particles, (e.g., water, alcohols, and the like). The preform is then formed by wet co-consolidation of the polymer and calcium phosphate particulate suspension.



In other embodiments, a preform is formed from a polymer foam, e.g., having open porosity (e.g., continuous). The polymer foam can be provided in a similar manner to the preparation of the polymer particles, but while dissolving the polymer at a slower mixing rate, with slower solvent removal, and at a higher  
5 fraction of polymer relative to solvent. Thus, the polymer foam is formed by dissolving the polymer in solvent (e.g., water, xylene, chloroform, toluene, methylene chloride, tetrahydrofuran, ethyl acetate, hexafluoroisopropanol, acetone, alcohols, and the like) while mixing followed by precipitation or gelation from the solution, followed by solvent removal via vacuum oven drying,  
10 distillation and collection, freeze drying, and the like. Additionally, the polymer foam and/or gel may be suspended in a suitable medium (e.g., water, alcohols, and the like) and repeatedly washed to remove residual traces of the solvent. In these embodiments, the co-processing includes infiltrating the polymer foam with a suspension (e.g., alcohols, in water and the like) of the calcium phosphate  
15 particles, so as to form the preform.

In still other embodiments, a preform is formed from a porous compact of the calcium phosphate reinforcement particles. The thermoplastic polymer is provided and infiltrated into the porous calcium phosphate compact. By way of example, the polymer can be provided molten, solvated (e.g., in a biocompatible  
20 medium, such as water or other medium that dissolves the thermoplastic), or as a polymerizing mixture comprising monomer, initiator, and, optionally, polymer powder and/or co-initiators (as discussed herein below). By way of example, the porous compact of the calcium phosphate reinforcement particles is produced, for example, by dry pressing the calcium phosphate particles and sintering (e.g., at  
25 temperatures of from about 600 °C to about 1000 °C) the dry pressed particles to form the compact. In the co-processing, the porous compact of the calcium phosphate reinforcement particles is infiltrated with the polymer.

Once the preform is formed, it is thermo-mechanically densified and deformed to form the composite biomaterial. By way of example, the preform can  
30 be thermo-mechanically densified and deformed via channel die forging, injection molding, extrusion, pultrusion, or the like. In addition, the thermo-mechanical

deformation and densification desirably can include aligning the calcium phosphate reinforcement particles morphologically and/or crystallographically. The composite can be delivered to the patient, for example, by way of surgical implantation.

- 5 In still further embodiments, where a major portion of the matrix is a thermoplastic polymer composition and the composite biomaterial is to be delivered by either percutaneous or surgical injection, the thermoplastic polymer matrix may also be provided by mixing combinations of polymer powders and monomers with the addition of initiators and co-initiators (e.g., benzoyl peroxide,
- 10 dimethylaniline, ascorbic acid, cumene hydroperoxide, tributylborane, sulfinic acid, 4-cyanovaleric acid, potassium persulfate, dimethoxybenzoine, benzoic-acid-phenylester, N,N-dimethyl p-toluidine, dihydroxy-ethyl-p-toluidine, and the like, and combinations thereof) to induce polymerization and hardening *in-situ* during composite co-processing. Exemplary monomers include, but are not limited to,
- 15 acrylic monomers such as, for example, methylmethacrylate (MMA), 2,2'-bis(methacryloyloxyphenyl) propane (bis-MEEP), bisphenol a polyethylene glycol diether dimethacrylate (bis-EMA), urethane dimethacrylate (UDMA), diphenyloxymethacrylate (DPMA), n-butylmethacrylate, tri(ethylene glycol) dimethacrylate (TEG-DMA), bisphenol a hydroxypropylmethacrylate (bis-GMA),
- 20 and the like, and combinations thereof. Additionally, stabilizers (e.g., hydroquinone, 2-hydroxy-4-methoxy-benzophenone, and the like, and combinations thereof) may be added to mixtures to prevent premature polymerization of the monomers. The calcium phosphate reinforcements may be provided and mixed into any part of the polymer mixture prior to, during or after
- 25 the polymer mixture is formed, yielding a flowable, polymerizing composite biomaterial. Additionally, the polymer and or composite mixture may be mixed under vacuum or centrifuged to minimize porosity caused by entrapped gases. The polymer mixture is viscous in nature and gradually hardens (or "cures") as polymerization progresses. Thus, prior to hardening, the composite biomaterial
- 30 may be shaped and/or delivered by means of viscous flow, including such processes as percutaneous or surgical injection, channel die forging, compression

molding, injection molding, extrusion, or the like. In addition, mechanical deformation during viscous flow desirably can include aligning the calcium phosphate reinforcement particles morphologically and/or crystallographically.

- One skilled in the art will recognize that the desired shape of the implant may be
- 5 formed *ex vivo* by mechanical deformation prior to hardening, by shaping or machining a bulk block of the biomaterial after hardening, or by either percutaneous or surgical injection of the biomaterial to the desired locus where it will harden *in vivo*.

- The following examples further illustrate the present invention but, of course,
- 10 should not be construed as in any way limiting its scope.

#### Examples 1-4: Exemplary HA Whisker Syntheses

These examples demonstrate the preparation of exemplary calcium phosphate, namely calcium hydroxyapatite ( $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ), reinforcement particles in the shape of "whiskers" with varied size and shape.

Homogeneous solutions containing 0.015M P, 0.025M Ca and 0.050M chelating acid were prepared. For each solution, 1.725 g of  $\text{H}_3\text{PO}_4$  and a chelating acid were first added to 1000 ml distilled, de-ionized water under moderate stirring at room temperature, before dissolving 1.853 g  $\text{Ca}(\text{OH})_2$ . The chelating acid was used to chelate Ca ions in solution and included one of the following:

5.124 g DL-lactic acid ( $\text{CH}_3\text{CHOHCO}_2\text{H}$ ), 2.302 g formic acid ( $\text{HCO}_2\text{H}$ ), 3.003 g glacial acetic acid ( $\text{CH}_3\text{CO}_2\text{H}$ ), or 5.110 g valeric acid ( $\text{CH}_3(\text{CH}_2)_3\text{CO}_2\text{H}$ ), which correspond to examples 1-4, respectively. Each solution was sealed to prevent evaporation and continuously stirred until the dissolution of  $\text{Ca}(\text{OH})_2$  was determined to be complete upon visual inspection (typically after 2 h). Solutions were then filtered, measured for pH, and stored in bottles purged with nitrogen gas. Each solution had pH = 4. If necessary,  $\text{HNO}_3$  or  $\text{NH}_4\text{OH}$  were added to achieve this pH.

HA whiskers were grown by precipitation from the homogenous reaction solutions in a PTFE-lined stainless steel pressure vessel. The vessel was filled with a 100 ml aliquot of the reaction solution, purged with nitrogen gas, and sealed. The reactor was heated by placing the entire vessel into an oven equilibrated at the desired reaction temperature. The temperature inside the reactor was measured with time by a thermocouple placed inside the TEFLON® liner and was shown to asymptotically reached the ambient oven temperature. The reaction was held at a final temperature of 200°C for 2 h (8 h total).

After reaction, the pressure vessel was removed from the oven and cooled to less than 100°C within 1 h using a water-cooled aluminum block and motorized fan. Precipitates were filtered from the supernatant solution using a Büchner funnel and washed under a continuous flow of 100 ml distilled, de-ionized water.

The filtrate was placed in a petri dish and dried in an oven at 80°C for at least 12 h.

The precipitate was identified as calcium hydroxyapatite by x-ray diffraction (XRD). The particle dimensions and whisker morphology of the precipitates was observed by optical microscopy and quantitatively measured using stereological techniques (Table 2).

Table 2: Average Size and Shape Measured for the HA Whiskers Synthesized

Example	Chelating Acid	avg. length (μm)	avg. width (μm)	avg. aspect ratio
1	DL-lactic acid	22.3	2.4	9.5
2	formic acid	19.3	2.3	8.7
3	acetic acid	25.9	2.5	10.7
4	valeric acid	43.1	4.3	11.3

#### Example 5: Exemplary HA-HDPE Composites

This example demonstrates the preparation of an exemplary high density polyethylene (HDPE) matrix reinforced with calcium phosphate, namely calcium hydroxyapatite ( $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ), reinforcement particles in the shape of “whiskers”. For comparison, specimens were made from the HDPE polymer matrix alone as well as the HDPE polymer matrix reinforced with a conventional, equiaxed HA powder using the same processing technique.

HA whiskers were grown by precipitation from a homogenous aqueous solution (similar to example 1), containing 0.05 M  $\text{Ca}(\text{OH})_2$ , 0.03 M  $\text{H}_3\text{PO}_4$ , and 0.10 M lactic acid, in a TEFLON® lined stainless steel pressure vessel at 200°C for 4 h. HDPE powder was prepared by dissolving commercially available HDPE pellets in boiling xylene, cooling the solution to form a gel, extracting the solvent, and homogenizing the precipitated polymer in ethanol.

The appropriate amounts of HDPE and HA powders were ultrasonically dispersed in ethanol at a solids loading of 13 vol%. The suspension was vacuum filtered in a 10 mm diameter mold to form a porous cylindrical composite preform. After drying, the preform was subsequently pressed in a 10 mm vacuum pellet die to 280 MPa at 25°C and again at 145°C. Apparent densities of greater than 97% were typically achieved. The densified preform was then placed vertically into a channel die forge and bilaterally extruded at 145°C into a 2.5 x 10 x 120 mm flat bar, from which ASTM D638 type V tensile bars were machined. Tensile tests were performed under atmospheric conditions and a displacement rate of 5 mm/min.

The degree of preferred crystallographic orientation was determined by x-ray diffraction (XRD). For comparison, human cortical bone specimens were taken from the proximal end of the femoral midshaft. Thick sections were deproteinized by soaking 72 h in 7% NaOCl. The Harris texture index (see, e.g., Harris and Peterson articles, *supra*) was used to semi-quantitatively measure the degree of preferred crystallographic orientation (see discussion herein above).

The particle size and morphology of all starting powders were observed by scanning electron microscopy (SEM), and are shown in Figs 4A-4C, respectively. The conventional HA (Fig. 4A) was equiaxed and spherical with an average particle size of 2-3  $\mu\text{m}$ . The whiskers (Fig. 4B) were on average 20  $\mu\text{m}$  in length with an average aspect ratio of 10. Note that the [002] crystallographic axis lies along the whisker length. The HDPE powder particles (Fig. 4C) were spherical and 10-30  $\mu\text{m}$  in diameter.

XRD patterns for human cortical bone specimens and an exemplary composite are shown in Figs. 5A and 5B. In both cases, the (002) peaks have a higher relative intensity on the longitudinal cross-sections (second pattern from top) than on the perpendicular cross-sections (the patterns above and below). Thus, HA crystals in both specimens have a preferred orientation in the longitudinal directions (vertical in the schematics). Harris texture index measurements provided a semi-quantitative estimate the degree of preferred orientation and are shown in Figs. 6A and 6B. As will be appreciated by those of

ordinary skill in the art, in FIGS. 6A and 6B, "hkl" corresponds to the Miller indices of specific crystallographic planes of the HA reinforcement particles. It is to be noted that each crystallographic plane listed in FIG. 6 (002, 210, 300) corresponds to a specific XRD peak in FIG. 5. It also is to be noted that a value of 1.0 corresponds to a random orientation distribution. Under the given processing conditions, a slightly higher but similar degree of preferred orientation was achieved in the synthetic composite compared to cortical bone. The preferred orientation in bone is known to be physiological in origin. In the HDPE-HA composite, whisker alignment was induced by shear stresses occurring along the flow field as the material extruded in the forge mold.

Mechanical tests demonstrated the improved mechanical properties of the HA whisker reinforced composites compared to the matrix alone as well as reinforcement with a conventional HA powder (Table 3). The enhanced mechanical properties over the conventional HA powder are attributed to the anisometric morphology of the whisker reinforcements and their preferred orientation ("alignment") along the direction of applied stress.

Table 3: Mechanical Properties of the Composites in Example 5

vol% HA	Reinforcement Phase	Ultimate Tensile Strength (MPa)	Tensile Modulus (GPa)
0	none	27	0.6
10	conventional HA	27	1.3
10	HA whiskers	27	1.0
30	conventional HA	23	1.4
30	HA whiskers	28	1.9

### Example 6: Exemplary HA-PMMA Bone Cement Composites

This example demonstrates the preparation of an exemplary  
5 poly(methylmethacrylate) (PMMA) matrix reinforced with calcium phosphate,  
namely calcium hydroxyapatite ( $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ), reinforcement particles in the  
shape of “whiskers”. For comparison, specimens were made from the PMMA  
polymer matrix alone as well as the PMMA polymer matrix reinforced with a  
conventional, equiaxed HA powder using the same processing technique.

10 HA whiskers were grown by precipitation from a homogenous aqueous  
solution (similar to example 1), containing 0.05 M  $\text{Ca}(\text{OH})_2$ , 0.03 M  $\text{H}_3\text{PO}_4$ , and  
0.10 M lactic acid, in a Teflon lined stainless steel pressure vessel at 200°C for 2  
h. A commercially available PMMA bone cement, Simplex P™ (Howmedica),  
was mixed according to manufacturer recommendations using a vacuum stirring  
15 bowl. However, the monomer and powder ratios were adjusted to accommodate  
incorporating varying volume fractions of the HA reinforcements. Prior to  
reaching the “dough” stage, the bone cements were added to a syringe and injected  
into ASTM D638 type V tensile specimen mold or into ASTM F571 compression  
specimen molds. All tests were performed under atmospheric conditions and a  
20 displacement rate of 5 mm/min.

The particle size and morphology of the HA reinforcement powders were  
observed by scanning electron microscopy (SEM), and are shown in Fig. 5. The  
conventional HA was equiaxed and spherical with an average particle size of 2-3  
 $\mu\text{m}$ . The whiskers were on average 20  $\mu\text{m}$  in length with an average aspect ratio  
25 of 10. Note that the [002] crystallographic axis lies along the whisker length.

Mechanical tests demonstrated the improved mechanical properties of the  
HA whisker reinforced composites compared to the matrix alone as well as  
reinforcement with a conventional HA powder (Table 4). The enhanced  
mechanical properties over the conventional HA powder are attributed to the  
30 anisometric morphology of the whisker reinforcements and their preferred  
orientation (“alignment”) along the direction of applied stress. Shear stresses  
caused by material flow during injection developed a preferred crystallographic



orientation of the HA whiskers within the matrix material and yielded anisotropic mechanical properties. The degree of preferred orientation in HA whisker reinforced specimens, like example 5, was similar to that measured in human cortical bone.

5

Table 4: Mechanical Properties of the Composites in Example 6.

vol% HA	Reinforcement Phase	Ultimate Tensile Strength (MPa)	Tensile Modulus (GPa)	Ultimate Compressive Strength (MPa)	Compressive Modulus (GPa)
0	none	37	1.2	129	1.6
10	conventional HA	23	1.4	117	1.6
10	<u>HA whiskers</u>	27	1.7	125	1.8

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

WHAT IS CLAIMED IS:

1. A composite biomaterial comprising:  
a matrix including a thermoplastic polymer, a calcium phosphate  
5 composition that can cure *in vivo*, or any combination thereof; and  
anisometric calcium phosphate reinforcement particles dispersed within the  
matrix.
2. The composite of claim 1, wherein the reinforcement particles have  
10 a mean aspect ratio (length along c-axis/length along a-axis) of from about 5 to  
about 50.
3. The composite of claim 2, wherein the mean aspect ratio is from  
about 10 to about 20.
- 15 4. The composite of claim 1, wherein at least some of the  
reinforcement particles are shaped like whiskers.
5. The composite of claim 1, wherein at least some of the  
20 reinforcement particles are shaped like platelets.
6. The composite of claim 1, wherein the reinforcement particles are  
present in an amount of from about 1% by volume of the composite to about 60%  
by volume of the composite.
- 25 7. The composite of claim 6, wherein the reinforcement particles are  
present in an amount of from about 40% by volume of the composite to about 60%  
by volume of the composite.

8. The composite of claim 1, wherein the reinforcement particles have dimensions of from about 1 micrometer to about 500 micrometers along the c-axis and from about 0.02 micrometers to about 20 micrometers along the a-axis.

5 9. The composite of claim 8, wherein the reinforcement particles have a length of from about 5 micrometers to about 50 micrometers along the c-axis and from about 0.1 micrometers to about 10 micrometers along the a-axis.

10 10. The composite of claim 1, wherein the matrix includes at least one thermoplastic that is non-bioresorbable.

11. The composite of claim 10, wherein the non-bioresorbable thermoplastic is selected from the group consisting of polyethylene, high density polyethylene (HDPE), ultra high molecular weight polyethylene (UHMWPE), low  
15 density polyethylene (LDPE), polybutylene, polystyrene, polyurethane, polyacrylates, polymethacrylates, polypropylene, copolymers thereof, and blends thereof.

12. The composite of claim 1, wherein the matrix includes at least one  
20 thermoplastic that is bioresorbable.

13. The composite of claim 12, wherein the bioresorbable thermoplastic is selected from the group consisting of poly(DL-lactide) (DLPLA), poly(L-lactide) (LPLA), poly(glycolide) (PGA), poly(e-caprolactone) (PCL),  
25 poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), copolymers or blends thereof, and combinations thereof.

30

14. The composite of claim 1, wherein the composite includes at least one non-bioresorbable thermoplastic and at least one bioresorbable thermoplastic.

15. The composite of claim 14, wherein the bioresorbable thermoplastic is graded from a surface of the matrix to an inner core of the matrix.

16. The composite of claim 1, wherein the matrix includes at least one calcium phosphate compound.

17. The composite of claim 16, wherein the matrix includes particulate or dissolved bioresorbable or non-bioresorbable thermoplastic.

18. The composite of claim 1, wherein at least some of the reinforcement particles are bioresorbable.

19. The composite of claim 18, wherein the bioresorbable reinforcement particles are graded from a surface of the matrix to an inner core of the matrix.

20. The composite of claim 1, wherein the matrix includes the calcium phosphate composition, and wherein the calcium phosphate composition is selected from the group consisting of amorphous calcium phosphate, biphasic calcium phosphate, calcium phosphate, dicalcium phosphate, dicalcium phosphate dihydrate, calcium hydroxyapatite, carbonated calcium hydroxyapatite, monocalcium phosphate, monocalcium phosphate monohydrate, octacalcium phosphate, tricalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, tetracalcium phosphate, and combinations thereof.

21. The composite of claim 20, wherein the calcium phosphate composition includes at least one dopant.

22. The composite of claim 1, wherein the anisometric calcium phosphate reinforcement particles are selected from the group consisting of amorphous calcium phosphate, biphasic calcium phosphate, calcium phosphate, dicalcium phosphate, dicalcium phosphate dihydrate, calcium hydroxyapatite, carbonated calcium hydroxyapatite, monocalcium phosphate, monocalcium phosphate monohydrate, octacalcium phosphate, tricalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, tetracalcium phosphate, and combinations thereof.
23. The composite of claim 22, wherein at least some of the anisometric calcium phosphate reinforcement particles include at least one dopant.
24. The composite of claim 1, further comprising at least one surface-active agent.
25. The composite of claim 1, further comprising at least one additive selected from the group consisting of growth factors, transcription factors, matrix metalloproteinases, peptides, proteins, and combinations thereof.
26. A prosthesis for replacement of bone comprising the composite of claim 1.
27. A method of preparing a composite biomaterial comprising (a) a matrix including at least one calcium phosphate composition that can be cured *in vivo* and (b) anisometric calcium phosphate reinforcement particles arranged within the matrix, said method comprising:
- providing the anisometric calcium phosphate reinforcement particles;
  - preparing the calcium phosphate composition from at least one calcium-containing compound and at least one phosphate-containing compound, wherein at least one of the calcium-containing compound and phosphate-containing compound is derived by a hydrothermal reaction; and

combining the anisometric calcium phosphate reinforcement particles with the calcium phosphate composition or with at least one of the calcium-containing compound or phosphate-containing compound prior to formation of the calcium phosphate composition.

5

28. The method of claim 27, wherein the anisometric calcium phosphate reinforcement particles are provided via a hydrothermal reaction.

29. The method of claim 29, wherein at least one of the calcium-  
10 containing compound or phosphate-containing compound is in the form of particles having a mean diameter of less than about 1 micrometer.

30. The method of claim 29, wherein at least one of the calcium-  
containing compound or phosphate-containing compound is in the form of  
15 particles having a mean diameter of from about 1 nanometers to about 500 nanometers.

31. The method of claim 27, wherein each of said calcium-containing  
compound and phosphate-containing compound is derived by a hydrothermal  
20 reaction.

32. The method of claim 27, wherein the anisometric calcium phosphate  
reinforcement particles are mixed with at least one of the calcium-containing  
compound or phosphate-containing compound prior to formation of the calcium  
25 phosphate composition.

33. The method of claim 27, wherein the anisometric calcium phosphate  
reinforcement particles are added after the calcium phosphate composition is  
formed.

30

34. The method of claim 27, wherein the calcium containing compound is selected from the group consisting of calcium hydroxide, calcium nitrate, calcium chloride, calcium carbonate, calcium lactate, calcium acetate, calcium citrate, calcium sulfate, calcium fluoride, calcium oxalate, amorphous calcium phosphate, biphasic calcium phosphate, calcium phosphate, dicalcium phosphate, dicalcium phosphate dihydrate, calcium hydroxyapatite, carbonated calcium hydroxyapatite, monocalcium phosphate, monocalcium phosphate monohydrate, octacalcium phosphate, tricalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, tetracalcium phosphate, and combinations thereof.

10

35. The method of claim 27, wherein the phosphate-containing compound is selected from the group consisting of phosphoric acid, fluorophosphoric acid, sodium orthophosphate, potassium orthophosphate, ammonium orthophosphate, amorphous calcium phosphate, biphasic calcium phosphate, calcium phosphate, dicalcium phosphate, dicalcium phosphate dihydrate, calcium hydroxyapatite, carbonated calcium hydroxyapatite, monocalcium phosphate, monocalcium phosphate monohydrate, octacalcium phosphate, tricalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, tetracalcium phosphate, and combinations thereof.

20

36. A method of preparing a composite biomaterial comprising (a) a matrix including at least one thermoplastic polymer and (b) anisometric calcium phosphate reinforcement particles arranged within the matrix, said method comprising:

25 providing the anisometric calcium phosphate reinforcement particles;  
providing the polymer;  
co-processing the polymer and the calcium phosphate reinforcement particles to obtain a substantially uniform mixture thereof; and  
deforming and/or densifying the mixture to form the composite  
30 biomaterial.

37. The method of claim 36, wherein the anisometric calcium phosphate reinforcement particles are provided via a hydrothermal reaction.

38. The method of claim 36, wherein said providing the polymer  
5 includes providing particles of the polymer in a suspension, wherein said providing the anisometric calcium phosphate reinforcement particles includes providing the reinforcement particles in the suspension or in a second suspension, and wherein said co-processing includes wet co-consolidation of the calcium phosphate reinforcement particles and the polymer particles to form a preform.

10

39. The method of claim 38, wherein the polymer particles are produced by dissolving the polymer in a solvent under mixing, followed by precipitation or gelation of the polymer from the solution, followed by solvent removal.

15

40. The method of claim 39, wherein the solvent removal is by way of vacuum oven drying, distillation and collection, or freeze drying.

41. The method of claim 36, wherein said providing the polymer  
20 includes providing a foam of polymer having continuous open porosity, and wherein said co-processing includes infiltrating the polymer foam with a suspension of the calcium phosphate reinforcement particles to form a preform.

42. The method of claim 41, wherein the polymer foam is produced by  
25 dissolving the polymer in a solvent under mixing, followed by precipitation or gelation of the polymer from the solution, followed by solvent removal.

43. The method of claim 42, wherein the solvent removal is by way of vacuum oven drying, distillation and collection, or freeze drying.

30



44. The method of claim 36, wherein said providing the anisometric calcium phosphate reinforcement particles includes providing a porous compact of the calcium phosphate reinforcement particles, said providing the polymer includes providing a molten or solvated polymer or as a polymerizing mixture comprising monomer and initiator, and, optionally polymer powder, co-initiator, and/or stabilizer, and wherein said co-processing includes infiltrating the porous compact of the calcium phosphate reinforcement particles with the polymer.

45. The method of claim 44, wherein the porous compact of the calcium phosphate reinforcement particles is produced by dry pressing calcium phosphate particles and sintering the dry pressed particles to form the compact.

46. The method of claim 45, wherein the sintering is at a temperature of from about 600 °C to about 1000 °C.

15

47. The method of claim 36, wherein said providing the polymer includes mixing monomer with an initiator, and, optionally, polymer powder and co-initiator, to form a polymer-forming mixture, and wherein said co-processing includes polymerizing and hardening the mixture *in situ*.

20

48. The method of claim 47, wherein said initiator and/or co-initiator is selected from the group consisting of benzoyl peroxide, dimethylaniline, ascorbic acid, cumene hydroperoxide, tributylborane, sulfinic acid, 4-cyanovaleric acid, potassium persulfate, dimethoxybenzoin, benzoic-acid-phenylester, N,N-dimethyl p-toluidine, dihydroxy-ethyl-p-toluidinebenzoyl peroxide, and any combination thereof.

25

49. The method of claim 47, wherein said monomer is selected from the group consisting of methylmethacrylate (MMA), 2,2'-bis(methacryloylethoxyphenyl) propane (bis-MEEP), bisphenol a polyethylene glycol diether dimethacrylate (bis-EMA), urethane dimethacrylate (UDMA),

30

diphenyloxymethacrylate (IPMA), n-butylmethacrylate, tri(ethylene glycol) dimethacrylate (TEG-DMA), bisphenol a hydroxypropylmethacrylate (bis-GMA), and any combination thereof.

5           50.    The method of claim 47, wherein said providing the polymer includes adding a stabilizer to prevent premature polymerization of the polymer.

          51.    The method of claim 50, wherein said stabilizer is selected from hydroquinone, 2-hydroxy-4-methoxy-benzophenone, or combinations thereof.

10

          52.    The method of claim 47, wherein said co-processing comprises combining said anisometric calcium phosphate reinforcement particles with said polymer-forming mixture prior to mixing the components thereof.

15           53.    The method of claim 47, wherein said co-processing comprises combining said anisometric calcium phosphate reinforcement particles with said polymer-forming mixture during polymerization.

          54.    The method of claim 36, wherein the deforming and/or densifying  
20 includes aligning the calcium phosphate reinforcement particles morphologically and/or crystallographically.

          55.    The method of claim 36, wherein the deforming and/or densifying occurs thermo-mechanically or mechanically.

25

          56.    The method of claim 56, wherein the thermo-mechanically deforming and/or densifying includes channel die forging.

          57.    The method of claim 56, wherein the thermo-mechanically or  
30 mechanically deforming and/or densifying includes compression molding or die pressing.

58. The method of claim 56, wherein the thermo-mechanically deforming and/or densifying includes injection molding.

5 59. The method of claim 56, wherein the thermo-mechanically deforming and/or densifying includes extrusion or pultrusion.

60. The method of claim 56, wherein the mechanically deforming and/or densifying includes the viscous flow of a molten or polymerizing polymer  
10 matrix.

61. The method of claim 60, wherein the viscous flow is achieved by percutaneous or surgical injection, channel die forging, compression molding, injection molding, or extrusion.

15

62. The method of claim 36, further comprising adding a surface-active agent.

1/3




Fig. 1




Fig. 2




Fig. 3

SUBSTITUTE SHEET (RULE 26)

2/3




Fig. 4a




Fig. 4b




Fig. 4c

SUBSTITUTE SHEET (RULE 26)

3/3




Fig. 5a




hkl			
002	0.5	1.9	0.6
210	0.9	0.3	1.1
300	0.9	0.5	0.9

Fig. 6a




Fig. 5b




hkl			
002	0.7	2.6	0.6
210	0.7	0.2	1.4
300	1.1	0.3	1.8

Fig. 6b

**VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT  
AM DEM GEBIET DES PATENTWESENS**

**PCT**

**INTERNATIONALER RECHERCHENBERICHT**

(Artikel 18 sowie Regeln 43 und 44 PCT)

<b>Aktenzeichen des Anmelders oder Anwalts</b> <b>H 3763 PCT</b>	<b>WEITERES VORGEHEN</b> siehe Mitteilung über die Übermittlung des internationalen Recherchenberichts (Formblatt PCT/ISA/220) sowie, soweit zutreffend, nachstehender Punkt 5	
<b>Internationales Aktenzeichen</b> <b>PCT/EP 99/ 09683</b>	<b>Internationales Anmeldedatum (Tag/Monat/Jahr)</b> <b>09/12/1999</b>	<b>(Frühestes) Prioritätsdatum (Tag/Monat/Jahr)</b> <b>18/12/1998</b>
<b>Anmelder</b>  <b>HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN et al</b>		

Dieser internationale Recherchenbericht wurde von der internationalen Recherchenbehörde erstellt und wird dem Anmelder gemäß Artikel 18 übermittelt. Eine Kopie wird dem internationalen Büro übermittelt.

Dieser internationale Recherchenbericht umfaßt insgesamt 2 Blätter.

☒ Darüber hinaus liegt ihm jeweils eine Kopie der in diesem Bericht genannten Unterlagen zum Stand der Technik bei.

**1. Grundlage des Berichts**

- a. Hinsichtlich der Sprache ist die internationale Recherche auf der Grundlage der internationalen Anmeldung in der Sprache durchgeführt worden, in der sie eingereicht wurde, sofern unter diesem Punkt nichts anderes angegeben ist.
- ☐ Die internationale Recherche ist auf der Grundlage einer bei der Behörde eingereichten Übersetzung der internationalen Anmeldung (Regel 23.1 b)) durchgeführt worden.
- b. Hinsichtlich der in der internationalen Anmeldung offenbarten Nucleotid- und/oder Aminosäuresequenz ist die internationale Recherche auf der Grundlage des Sequenzprotokolls durchgeführt worden, das
- ☐ in der internationalen Anmeldung in schriftlicher Form enthalten ist.
- ☐ zusammen mit der internationalen Anmeldung in computerlesbarer Form eingereicht worden ist.
- ☐ bei der Behörde nachträglich in schriftlicher Form eingereicht worden ist.
- ☐ bei der Behörde nachträglich in computerlesbarer Form eingereicht worden ist.
- ☐ Die Erklärung, daß das nachträglich eingereichte schriftliche Sequenzprotokoll nicht über den Offenbarungsgehalt der internationalen Anmeldung im Anmeldezeitpunkt hinausgeht, wurde vorgelegt.
- ☐ Die Erklärung, daß die in computerlesbarer Form erfaßten Informationen dem schriftlichen Sequenzprotokoll entsprechen, wurde vorgelegt.

2. ☐ Bestimmte Ansprüche haben sich als nicht recherchierbar erwiesen (siehe Feld I).

3. ☐ Mangelnde Einheitlichkeit der Erfindung (siehe Feld II).

**4. Hinsichtlich der Bezeichnung der Erfindung**

- ☒ wird der vom Anmelder eingereichte Wortlaut genehmigt.
- ☐ wurde der Wortlaut von der Behörde wie folgt festgesetzt:

**5. Hinsichtlich der Zusammenfassung**

- ☒ wird der vom Anmelder eingereichte Wortlaut genehmigt.
- ☐ wird der Wortlaut nach Regel 38.2b) in der in Feld III angegebenen Fassung von der Behörde festgesetzt. Der Anmelder kann der Behörde innerhalb eines Monats nach dem Datum der Absendung dieses internationalen Recherchenberichts eine Stellungnahme vorlegen.

6. Folgende Abbildung der Zeichnungen ist mit der Zusammenfassung zu veröffentlichen: Abb. Nr. \_\_\_\_\_

- ☐ wie vom Anmelder vorgeschlagen ☐ keine der Abb.
- ☐ weil der Anmelder selbst keine Abbildung vorgeschlagen hat.
- ☐ weil diese Abbildung die Erfindung besser kennzeichnet.

# INTERNATIONALER RECHERCHENBERICHT

Internationales Aktenzeichen

P 99/09683

A. KLASSIFIZIERUNG DES ANMELDUNGSGEGENSTANDES  
IPK 7 A61K7/16 A61K7/18

Nach der Internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK

## B. RECHERCHIERTE GEBIETE

Recherchiertes Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole)  
IPK 7 A61K

Recherchierte aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen

Während der Internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)

## C. ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
X	GB 1 110 900 A (COLGATE-PALMOLIVE) Seite 2, Zeile 4 - Zeile 100; Ansprüche 1-9	1-4, 6, 7
X	GB 2 206 338 A (SANGI K.K.) 5. Januar 1989 (1989-01-05) Seite 8, Absatz 1; Ansprüche 1-11	1, 2, 4, 6, 7
X	EP 0 208 790 A (MITSUBISHI RAYON) 21. Januar 1987 (1987-01-21) Ansprüche 1-8	1-4
X	EP 0 732 343 A (MITSUBISHI CHEMICAL) 18. September 1996 (1996-09-18) Ansprüche 1-17	1, 2, 4

☐ Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen

☒ Siehe Anhang Patentfamilie

\* Besondere Kategorien von angegebenen Veröffentlichungen :

"A" Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist

"E" älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist

"L" Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt)

"O" Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht

"P" Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist

"T" Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist

"X" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfinderischer Tätigkeit beruhend betrachtet werden

"Y" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfinderischer Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist

"&" Veröffentlichung, die Mitglied derselben Patentfamilie ist

Datum des Abschlusses der Internationalen Recherche

3. April 2000

Absendedatum des Internationalen Recherchenberichts

11/04/2000

Name und Postanschrift der Internationalen Recherchenbehörde  
Europäisches Patentamt, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Bevollmächtigter Bediensteter

Fouquier, J-P



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 99/09683

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1110900 A		BE 680068 A	03-10-1966
		DE 1617371 A	01-04-1971
		FR 5579 M	27-11-1967
		FR 1484762 A	27-09-1967
		IT 1002501 B	20-05-1976
		NL 6605904 A	04-11-1966
		NO 115750 B	25-11-1968
		OA 2079 A	05-05-1970
GB 2206338 A	05-01-1989	CA 1327256 A	01-03-1994
		DE 3816237 A	12-01-1989
		FR 2617398 A	06-01-1989
		IT 1218019 B	30-03-1990
		JP 1110608 A	27-04-1989
		JP 2724307 B	09-03-1998
		US 5135396 A	04-08-1992
EP 208790 A	21-01-1987	JP 61163903 A	24-07-1986
		JP 61174248 A	05-08-1986
		AU 5356786 A	13-08-1986
		WO 8604337 A	31-07-1986
EP 732343 A	18-09-1996	JP 8253510 A	01-10-1996
		CA 2170723 A	15-09-1996
		CN 1141302 A	29-01-1997
		DE 69602653 D	08-07-1999
		DE 69602653 T	28-10-1999
		US 5889285 A	30-03-1999